Raw Sequence Listing Error Summary

<u>ERROR DETECTED</u>   <u>SUGGESTED CORRECTION</u>   SERIAL NUMBER: _09/825,517_

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1 _____ Wrapped Nucleics

The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".

2 _____ Wrapped Aminos

The amino acid number/text at the end of each line "wrapped " down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".

3 _____ Incorrect Line Length

The rules require that a line not exceed 72 characters in length. This includes spaces.

4 _____ Misaligned Amino Acid
Numbering

The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs
between the numbering. It is recommended to delete any tabs and use spacing between the numbers.

5 _____ Non-ASCII

This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.

6 _____ Variable Length

Sequence(s) _____ contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and
indicate in the (ix) feature section that some may be missing.

7 _____ PatentIn ver. 2.0 "bug"

A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid
sequence(s) _____. Normally, PatentIn would automatically generate this section from the
previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section
to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223>
sections for Artificial or Unknown sequences.

8 _____ Skipped Sequences
(OLD RULES)

Sequence(s) _____ missing. If intentional, please use the following format for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).

9 _____ Skipped Sequences
(NEW RULES)

Sequence(s) _____ missing. If intentional, please use the following format for each skipped sequence.
<210> sequence id number
<400> sequence id number
000

10 _____ Use of n's or Xaa's
(NEW RULES)

Use of n's and/or Xaa's have been detected in the Sequence Listing.
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

11 _____ Use of "Artificial"
(NEW RULES)

Use of "Artificial" only as "<213> Organism" response is incomplete, per 1.823(b) of New Sequence Rules.
Valid response is Artificial Sequence.

_108_

12 _____ Use of <220>Feature
(NEW RULES)

Sequence(s) _____ are missing the <220>Feature and associated headings.
Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial Sequence" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32)   (Sec. 1.823 of new Rules)

13 _____ PatentIn ver. 2.0 "bug"

Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted
file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.

AMC - Biotechnology Systems Branch - 4/06/2001

```
        RAW SEQUENCE LISTING              DATE: 04/19/2001
        PATENT APPLICATION:  US/09/825,517    TIME: 12:02:25

        Input Set : A:\Dyax-161.app
        Output Set: N:\CRF3\04192001\I825517.raw
```

Does Not Comply
Corrected Diskette Needed

```
 3 <110> APPLICANT: Rondon, Isaac J
 4        Ladner, Robert C
 6 <120> TITLE OF INVENTION: BINDING PEPTIDES FOR CARCINOEMBRYONIC ANTIGEN (CEA)
 8 <130> FILE REFERENCE: Sequence Listing DYX-016.1 US
10 <140> CURRENT APPLICATION NUMBER: US/09/825,517
11 <141> CURRENT FILING DATE: 2001-04-03
13 <150> PRIOR APPLICATION NUMBER: US 09/541345
14 <151> PRIOR FILING DATE: 2000-04-03
16 <160> NUMBER OF SEQ ID NOS: 151
18 <170> SOFTWARE: PatentIn Ver. 2.1
20 <210> SEQ ID NO: 1
21 <211> LENGTH: 16
22 <212> TYPE: PRT
23 <213> ORGANISM: Artificial Sequence
25 <220> FEATURE:
26 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
27        polypeptide
29 <220> FEATURE:
30 <221> NAME/KEY: VARIANT
31 <222> LOCATION: (1)
32 <223> OTHER INFORMATION: Xaa is Asn, Asp or is absent
34 <220> FEATURE:
35 <221> NAME/KEY: VARIANT
36 <222> LOCATION: (2)
37 <223> OTHER INFORMATION: Xaa is Trp
39 <220> FEATURE:
40 <221> NAME/KEY: VARIANT
41 <222> LOCATION: (3)
42 <223> OTHER INFORMATION: Xaa is Asp, Phe or Val
44 <220> FEATURE:
45 <221> NAME/KEY: VARIANT
46 <222> LOCATION: (5)
47 <223> OTHER INFORMATION: Xaa is Asn, Glu or Met
49 <220> FEATURE:
50 <221> NAME/KEY: VARIANT
51 <222> LOCATION: (6)
52 <223> OTHER INFORMATION: Xaa is Asn, Leu, Met or Phe
54 <220> FEATURE:
55 <221> NAME/KEY: VARIANT
56 <222> LOCATION: (7)
57 <223> OTHER INFORMATION: Xaa is Asp, Gly, Ile, Lys, Phe or Thr
59 <220> FEATURE:
60 <221> NAME/KEY: VARIANT
61 <222> LOCATION: (8)
62 <223> OTHER INFORMATION: Xaa is Ala, Gln, gly Lys or Thr
64 <220> FEATURE:
65 <221> NAME/KEY: VARIANT
```

C--> (line 10)

pp 1-3,6

Gly, ← add comma (gly) circled

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/825,517

DATE: 04/19/2001
TIME: 12:02:25

Input Set : **A:\Dyax-161.app**
Output Set: **N:\CRF3\04192001\I825517.raw**

```
 66 <222> LOCATION: (9)
 67 <223> OTHER INFORMATION: Xaa is Arg, Asn, Asp, Glu or Gly
 69 <220> FEATURE:
 70 <221> NAME/KEY: VARIANT
 71 <222> LOCATION: (10)
 72 <223> OTHER INFORMATION: Xaa is Gln, Leu or Gly
 74 <220> FEATURE:
 75 <221> NAME/KEY: VARIANT
 76 <222> LOCATION: (11)
 77 <223> OTHER INFORMATION: Xaa is Ala, Trp or Tyr
 79 <220> FEATURE:
 80 <221> NAME/KEY: VARIANT
 81 <222> LOCATION: (12)
 82 <223> OTHER INFORMATION: Xaa is Ala, Gly, His, Phe, Thr or Val
 84 <220> FEATURE:
 85 <221> NAME/KEY: VARIANT
 86 <222> LOCATION: (14)
 87 <223> OTHER INFORMATION: Xaa is Asn, Gln, Phe, Ser or Val
 89 <220> FEATURE:
 90 <221> NAME/KEY: VARIANT
 91 <222> LOCATION: (15)
 92 <223> OTHER INFORMATION: Xaa is Arg, Leu, Pro or Ser
 94 <220> FEATURE:
 95 <221> NAME/KEY: VARIANT
 96 <222> LOCATION: (16)
 97 <223> OTHER INFORMATION: Xaa is Leu, Ser, Trp or Tyr
 99 <400> SEQUENCE: 1
100 Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
101   1           5                 10                  15
104 <210> SEQ ID NO: 2
105 <211> LENGTH: 16
106 <212> TYPE: PRT
107 <213> ORGANISM: Artificial Sequence
109 <220> FEATURE:
110 <223> OTHER INFORMATION: Description of Artificial Sequence: family of
111        preferred CEA binding moieties
113 <220> FEATURE:
114 <221> NAME/KEY: VARIANT
115 <222> LOCATION: (1)
116 <223> OTHER INFORMATION: Xaa is Asn or Asp
118 <220> FEATURE:
119 <221> NAME/KEY: VARIANT
120 <222> LOCATION: (6)
121 <223> OTHER INFORMATION: Xaa is Ph, Met, Leu or Asn
123 <220> FEATURE:
124 <221> NAME/KEY: VARIANT
125 <222> LOCATION: (7)
126 <223> OTHER INFORMATION: Xaa is Asp, Gly, Ile, Lys, Phe or Thr
128 <220> FEATURE:
```

W-->

Phe?

RAW SEQUENCE LISTING   DATE: 04/19/2001
PATENT APPLICATION: US/09/825,517   TIME: 12:02:25

Input Set : A:\Dyax-161.app
Output Set: N:\CRF3\04192001\I825517.raw

```
129 <221> NAME/KEY: VARIANT
130 <222> LOCATION: (9)
131 <223> OTHER INFORMATION: Xaa is Arg, Asn, Asp, Glu, Gly or Trp
133 <220> FEATURE:
134 <221> NAME/KEY: VARIANT
135 <222> LOCATION: (12)
136 <223> OTHER INFORMATION: Xaa is Ala, Gly, His, Phe, Thr, Tyr or Val
138 <220> FEATURE:
139 <221> NAME/KEY: VARIANT
140 <222> LOCATION: (15)
141 <223> OTHER INFORMATION: Xaa is Arg, Leu, Pro or Ser
143 <220> FEATURE:
144 <221> NAME/KEY: VARIANT
145 <222> LOCATION: (16)
146 <223> OTHER INFORMATION: Xaa is Leu, Ser, Trp or Tyr
148 <400> SEQUENCE: 2
149 Xaa Trp Val Cys Glu Xaa Xaa Lys Xaa Gln Trp Xaa Cys Asn Xaa Xaa
150   1               5                  10                  15
153 <210> SEQ ID NO: 3
154 <211> LENGTH: 10
155 <212> TYPE: PRT
156 <213> ORGANISM: Artificial Sequence
158 <220> FEATURE:
159 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
160       loop
162 <220> FEATURE:
163 <221> NAME/KEY: VARIANT
164 <222> LOCATION: (2)
165 <223> OTHER INFORMATION: Xaa is Asn, Glu or Met
167 <220> FEATURE:
168 <221> NAME/KEY: VARIANT
169 <222> LOCATION: (3)
170 <223> OTHER INFORMATION: Xaa is Asn, Leu, Net or Phe
172 <220> FEATURE:
173 <221> NAME/KEY: VARIANT
174 <222> LOCATION: (4)
175 <223> OTHER INFORMATION: Xaa is Asp, Gly, Ile, Lys, Phe or Thr
177 <220> FEATURE:
178 <221> NAME/KEY: VARIANT
179 <222> LOCATION: (5)
180 <223> OTHER INFORMATION: Xaa is Ala, Gln, Gly, Lys or Thr
182 <220> FEATURE:
183 <221> NAME/KEY: VARIANT
184 <222> LOCATION: (6)
185 <223> OTHER INFORMATION: Xaa is Arg, Asn, Asp, Glu or Gly
187 <220> FEATURE:
188 <221> NAME/KEY: VARIANT
189 <222> LOCATION: (7)
190 <223> OTHER INFORMATION: Xaa is Gln, Gly or Leu
```

W--> 149 (handwritten annotation: "Met?" with circle around "Net" on line 170)

```
192 <220> FEATURE:
193 <221> NAME/KEY: VARIANT
194 <222> LOCATION: (8)
195 <223> OTHER INFORMATION: Xaa is Ala, Trp or Tyr
197 <220> FEATURE:
198 <221> NAME/KEY: VARIANT
199 <222> LOCATION: (9)
200 <223> OTHER INFORMATION: Xaa is Ala, Gly, His, Phe, Thr or Val
202 <400> SEQUENCE: 3
203 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
204   1               5                   10
207 <210> SEQ ID NO: 4
208 <211> LENGTH: 16
209 <212> TYPE: PRT
210 <213> ORGANISM: Artificial Sequence
212 <220> FEATURE:
213 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
214       polypeptide
216 <400> SEQUENCE: 4
217 Asn Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asn Ser Tyr
218   1               5                   10                  15
221 <210> SEQ ID NO: 5
222 <211> LENGTH: 16
223 <212> TYPE: PRT
224 <213> ORGANISM: Artificial Sequence
226 <220> FEATURE:
227 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
228       polypeptide
230 <400> SEQUENCE: 5
231 Asp Trp Val Cys Glu Asn Lys Lys Asp Gln Trp Thr Cys Asn Leu Leu
232   1               5                   10                  15
235 <210> SEQ ID NO: 6
236 <211> LENGTH: 16
237 <212> TYPE: PRT
238 <213> ORGANISM: Artificial Sequence
240 <220> FEATURE:
241 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
242       polypeptide
244 <400> SEQUENCE: 6
245 Asn Trp Asp Cys Met Phe Gly Ala Glu Gly Trp Ala Cys Ser Pro Trp
246   1               5                   10                  15
249 <210> SEQ ID NO: 7
250 <211> LENGTH: 16
251 <212> TYPE: PRT
252 <213> ORGANISM: Artificial Sequence
254 <220> FEATURE:
255 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
256       polypeptide
258 <400> SEQUENCE: 7
```

W--> (marker pointing at line 203)

● ●

RAW SEQUENCE LISTING   DATE: 04/19/2001
PATENT APPLICATION: US/09/825,517   TIME: 12:02:25

Input Set : **A:\Dyax-161.app**
Output Set: **N:\CRF3\04192001\I825517.raw**

259 Asp Trp Val Cys Glu Lys Thr Thr Gly Gly Tyr Val Cys Gln Pro Leu
260   1   5   10   15
263 <210> SEQ ID NO: 8
264 <211> LENGTH: 16
265 <212> TYPE: PRT
266 <213> ORGANISM: Artificial Sequence
268 <220> FEATURE:
269 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
270   polypeptide
272 <400> SEQUENCE: 8
273 Asn Trp Phe Cys Glu Met Ile Gly Arg Gln Trp Gly Cys Val Pro Ser
274   1   5   10   15
277 <210> SEQ ID NO: 9
278 <211> LENGTH: 16
279 <212> TYPE: PRT
280 <213> ORGANISM: Artificial Sequence
282 <220> FEATURE:
283 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
284   polypeptide
286 <400> SEQUENCE: 9
287 Asp Trp Val Cys Asn Phe Asp Gln Gly Leu Ala His Cys Phe Pro Ser
288   1   5   10   15
291 <210> SEQ ID NO: 10
292 <211> LENGTH: 12
293 <212> TYPE: PRT
294 <213> ORGANISM: Artificial Sequence
296 <220> FEATURE:
297 <223> OTHER INFORMATION: Description of Artificial Sequence: parental
298   domain for design of microprotein display library
300 <220> FEATURE:
301 <221> NAME/KEY: VARIANT
302 <222> LOCATION: (1)..(12)
303 <223> OTHER INFORMATION: amino acid positions 4 and 9 are invariant Cys;
304   all other positions Xaa are varied but not Cys, to
305   provide a library of 2x10(8) different peptides
306   based on the template sequence
308 <400> SEQUENCE: 10
W--> 309 Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
310   1   `   .   5   ·   10
313 <210> SEQ ID NO: 11
314 <211> LENGTH: 11
315 <212> TYPE: PRT
316 <213> ORGANISM: Artificial Sequence
318 <220> FEATURE:
319 <223> OTHER INFORMATION: Description of Artificial Sequence: parental
320   domain for design of microprotein display library
322 <220> FEATURE:
323 <221> NAME/KEY: VARIANT
324 <222> LOCATION: (1)..(11)

```
<210> 108
<211> 16
<212> PRT
<213> Artificial Sequence    see item 12 on Eval Summary Sheet

<400> 108
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asn Glu Ala
1               5                   10                  15
```

Please Note:
Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Input Set : **A:\Dyax-161.app**
Output Set: **N:\CRF3\04192001\I825517.raw**

```
L:10 M:270 C: Current Application Number differs, Replaced Current Application Number
L:100 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:149 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:203 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:309 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:331 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:353 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:375 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13
L:400 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:420 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15
L:440 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:465 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17
L:500 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18
L:530 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:560 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:628 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:739 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29
L:759 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:30
L:779 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:804 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:839 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:869 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
L:899 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:978 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:1981 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:1981 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:2054 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:110
L:2144 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:111
```

||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Creation date: 10-14-2003
Indexing Officer: HNGUYEN28 - HAO NGUYEN
Team: OIPEBackFileIndexing
Dossier: 09825517

Legal Date: 06-01-2001

No.	Doccode	Number of pages
1	CTMS	2

Total number of pages: 2

Remarks:

Order of re-scan issued on ....